Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern.
Cho H, Gonzales-Wartz KK, Huang D, Yuan M, Peterson M, Liang J, Beutler N, Torres JL, Cong Y, Postnikova E, Bangaru S, Talana CA, Shi W, Yang ES, Zhang Y, Leung K, Wang L, Peng L, Skinner J, Li S, Wu NC, Liu H, Dacon C, Moyer T, Cohen M, Zhao M, Lee FE, Weinberg RS, Douagi I, Gross R, Schmaljohn C, Pegu A, Mascola JR, Holbrook M, Nemazee D, Rogers TF, Ward AB, Wilson IA, Crompton PD, Tan J
Sci Transl Med. 2021 Oct 20;13(616):eabj5413. doi: 10.1126/scitranslmed.abj5413. Epub 2021 Oct 20.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 172319 | pcDNA3.3-SARS2-B.1.617.1 | expressing SARS-CoV-2 B.1.617.1 (kappa strain) spike protein for pseudovirus production |
| 172320 | pcDNA3.3-SARS2-B.1.617.2 | expressing SARS-CoV-2 B.1.617.2 spike protein (delta strain) for pseudovirus production. |
| 177578 | pcDNA3.3_SARS2_Mu | expressing SARS-CoV-2 B.1.621 (Mu) spike protein for pseudovirus production |
| 177579 | pcDNA3.3_SARS2_Lambda | expressing SARS-CoV-2 C.37 (lambda) spike protein for pseudovirus production |